These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32147592)

  • 1. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.
    Sun Y; Wu X; Zhou J; Meng T; Wang B; Chen S; Liu H; Wang T; Zhao X; Wu S; Kong Y; Ou X; Wee A; Theise ND; Qiu C; Zhang W; Lu F; Jia J; You H
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2582-2591.e6. PubMed ID: 32147592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B.
    Sanai FM; Helmy A; Bzeizi KI; Babatin MA; Al-Qahtani A; Al-Ashgar HA; Al-Mdani AS; Al-Akwaa A; Almutharea S; Khan MQ; Alghamdi AS; Farah T; Al-Hamoudi W; Saadeh M; Abdo AA
    J Viral Hepat; 2011 Jul; 18(7):e217-25. PubMed ID: 21692936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B.
    Chang XJ; Sun C; Chen Y; Li XD; Yu ZJ; Dong Z; Bai WL; Wang XD; Li ZQ; Chen D; Du WJ; Liao H; Jiang QY; Sun LJ; Li YY; Zhang CH; Xu DP; Chen YP; Li Q; Yang YP
    World J Gastroenterol; 2019 Aug; 25(32):4764-4778. PubMed ID: 31528100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study.
    Wang T; Smith DA; Campbell C; Mokaya J; Freeman O; Salih H; McNaughton AL; Cripps S; Várnai KA; Noble T; Woods K; Collier J; Jeffery K; Davies J; Barnes E; Matthews PC
    BMC Infect Dis; 2021 Jun; 21(1):610. PubMed ID: 34174833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Qualitative pathological assessment of liver fibrosis regression after antiviral therapy in patients with chronic hepatitis B].
    Sun YM; Zhou JL; Wang L; Wu XN; Chen YP; Piao HX; Lu LG; Jiang W; Xu YQ; Feng B; Nan YM; Xie W; Chen GF; Zheng HW; Li H; Ding HG; Liu H; Lyu FD; Shao C; Wang TL; Ou XJ; Wang BQ; Chen SY; You H; Jia JD
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):819-826. PubMed ID: 29325275
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum vitamin D and vitamin-D-binding protein levels in children with chronic hepatitis B.
    Huang CZ; Zhang J; Zhang L; Yu CH; Mo Y; Mo LY
    World J Gastroenterol; 2021 Jan; 27(3):255-266. PubMed ID: 33519140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
    Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
    World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
    Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
    Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection.
    Li F; Li X; Yan T; Liu Y; Cheng Y; Xu Z; Shao Q; Liao H; Huang P; Li J; Chen GF; Xu D
    Hepatol Int; 2018 Mar; 12(2):107-117. PubMed ID: 29651701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication.
    Praneenararat S; Chamroonkul N; Sripongpun P; Kanngurn S; Jarumanokul R; Piratvisuth T
    BMC Gastroenterol; 2014 Dec; 14():218. PubMed ID: 25523185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers.
    Chang KC; Chang MH; Lee CN; Chang CH; Wu JF; Ni YH; Wen WH; Shyu MK; Lai MW; Chen SM; Hu JJ; Lin HH; Hsu JJ; Mu SC; Lin YC; Liu CJ; Chen DS; Lin LH; Chen HL;
    Aliment Pharmacol Ther; 2019 Aug; 50(3):306-316. PubMed ID: 31271463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between hepatitis B surface antigen, HBV DNA quantity and liver fibrosis severity].
    Gao Y; Zou G; Ye J; Pan G; Rao J; Li F; Wei Y; Li X
    Zhonghua Gan Zang Bing Za Zhi; 2015 Apr; 23(4):254-7. PubMed ID: 26133815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of significant fibrosis in chronic hepatitis B patients with low viremia.
    Abdo AA; Bzeizi KI; Babatin MA; AlSohaibani F; AlMana H; Alsaad KO; AlGhamdi H; Al-Hamoudi W; AlSwat K; AlFaleh FZ; Myers RP; Sanai FM
    J Clin Gastroenterol; 2014 Jul; 48(6):e50-6. PubMed ID: 24072073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
    Boyd A; Bottero J; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Serfaty L; Lacombe K
    J Int AIDS Soc; 2017 Feb; 20(1):21426. PubMed ID: 28362068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors.
    Hsu CW; Liang KH; Lin CL; Wang TH; Yeh CT
    BMC Infect Dis; 2017 Jan; 17(1):9. PubMed ID: 28056849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.